{
  "source": "Global Wire",
  "source_name": "Global Wire",
  "meta_source_name": "Global Wire",
  "source_guid": "src-global-wire",
  "trust_level": 10,
  "source_type": "NEWS_WIRE",
  "group_guid": "group-simulation",
  "event_type": "OTHER",
  "published_at": "2025-12-12T04:50:05.254874",
  "upload_as_group": "group-simulation",
  "token": "eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJqdGkiOiJkMGQ2MjRlNC00ODZlLTQ0ZGMtOTIyYS1lZmY2ZjljZDNkNjUiLCJncm91cHMiOlsiYWRtaW4iXSwiaWF0IjoxNzY4ODU2Mzk1LCJleHAiOjE4MDAzOTIzOTUsIm5iZiI6MTc2ODg1NjM5NSwiYXVkIjoiZ29mci1hcGkifQ.0heNp4ApFlM0B12NtO6MwO46cp-1xGSE09XiYnr9zkk",
  "title": "Update regarding the drugmaker",
  "story_body": "GENETIC THERAPEUTICS CORP ANNOUNCES APPOINTMENT OF NEW DIRECTOR OF CORPORATE COMMUNICATIONS\n\nBOSTON, MA - January 15, 2024, 08:30 EST - Genetic Therapeutics Corp (NASDAQ: GENE), a biopharmaceutical company focused on rare disease treatments, announced today the appointment of Patricia Morrison to the position of Director of Corporate Communications, effective February 1, 2024.\n\nMorrison will report directly to Chief Operating Officer David Chen and will oversee all internal and external communications activities for Genetic Therapeutics Corp. She will be responsible for media relations, employee communications, and corporate messaging initiatives.\n\nMorrison joins Genetic Therapeutics Corp from her previous role as Senior Communications Manager at a healthcare consulting firm based in Philadelphia, where she worked for six years. She holds a Bachelor of Arts degree in Communications from Boston University and a Master of Science degree in Public Relations from Syracuse University.\n\n\"We are pleased to welcome Patricia Morrison to Genetic Therapeutics Corp,\" stated David Chen, Chief Operating Officer, in a prepared statement. \"Her experience in healthcare communications will support our ongoing efforts to effectively communicate with stakeholders.\"\n\nMorrison replaces former Director of Corporate Communications Robert Williams, who departed Genetic Therapeutics Corp in November 2023 to pursue other opportunities. The position had been vacant for approximately two months prior to this appointment.\n\nThe appointment does not affect Genetic Therapeutics Corp's current operational structure or strategic priorities. The company maintains its existing corporate communications framework and external relations protocols.\n\nGenetic Therapeutics Corp currently employs approximately 340 full-time employees across its Boston headquarters and research facilities. The company specializes in developing treatments for rare genetic disorders and maintains a pipeline of therapies in various stages of clinical development.\n\nThis personnel change is part of routine workforce management and does not indicate any shift in corporate strategy or business operations. Genetic Therapeutics Corp continues to execute on its stated business plan as outlined in its most recent quarterly filing with the Securities and Exchange Commission.\n\nNo additional organizational changes were announced at this time.",
  "validation_metadata": {
    "scenario": "Standard Filler",
    "base_ticker": "GENE",
    "expected_tier": "STANDARD",
    "expected_event": "OTHER",
    "expected_relevant_clients": [],
    "relationship_hops": 0,
    "expected_feed_rank_range": "1-50",
    "validation_rules": {
      "min_score": 0,
      "max_score": 49,
      "expected_tier": "STANDARD",
      "must_match_event": false,
      "expected_event": "OTHER",
      "expected_entities": [],
      "expected_relevant_clients": [],
      "relationship_hops": 0,
      "expected_feed_rank_range": "1-50"
    }
  }
}